Literature DB >> 6998240

Insulinopenia in impaired glucose tolerance preservation of insulin response to I.V. arginine and tolbutamide.

J P Monson, L J Borthwick, G S Spathis, S R Bloom.   

Abstract

Immunoreactive insulin (IRI) response to successive i.v. injections of glucose (0.3 g/kg), arginine (5 g) and tolbutamide (20 mg/kg) was measured in 11 non-obese patients with mild glucose intolerance and 11 control subjects. In 3 of the patients the IRI response to i.v. arginine and subsequent i.v. glucose was also measured. The mean peak IRI level following glucose was grossly diminished in the patients compared to controls but peak IRI levels following arginine and tolbutamide were similar in the two groups. Administering arginine prior to glucose in the 3 patients tested resulted in a lowering of the IRI response to arginine but no increase in the IRI response to glucose. The decreased IRI response to i.v. glucose associated with an adequate response to i.v. arginine and tolbutamide in these patients suggests a failure of the B-cell sensor mechanism for glucose and may provide a physiological explanation for the recognized value of restricting carbohydrate relative to protein in the treatment of this condition. Any defect in the sensor mechanism for arginine appears quantitatively much less severe than that to glucose.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6998240     DOI: 10.1007/bf02582071

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  23 in total

1.  Amino acid modulation of glucose-induced insulin and glucagon release in diabetic patients.

Authors:  Y Seino; M Ikeda; K Nakane; H Nakahara; S Seino
Journal:  Metabolism       Date:  1977-08       Impact factor: 8.694

2.  Synergistic effect of essential amino acids and glucose upon insulin secretion in man.

Authors:  J C Floyd; S S Fajans; S Pek; C A Thiffault; R F Knopf; J W Conn
Journal:  Diabetes       Date:  1970-02       Impact factor: 9.461

3.  Effects of single and multiple pulses of arginine on insulin release in man.

Authors:  D Rabinowitz; I Spitz; B Gonen; E Paran
Journal:  J Clin Endocrinol Metab       Date:  1973-05       Impact factor: 5.958

4.  Studies in prediabetes. Insulin response to oral glucose, intravenous tolbutamide and rapid intravenous glucose infusion in genetic prediabetics.

Authors:  M Serrano-Rios; F Ramos; J L Rodriguez-Miñon; F Vivanco
Journal:  Diabetologia       Date:  1970-08       Impact factor: 10.122

5.  Enhancement of arginine-induced insulin secretion in man by prior administration of glucose.

Authors:  S R Levin; J H Karam; S Hane; G M Grodsky; P H Forsham
Journal:  Diabetes       Date:  1971-03       Impact factor: 9.461

6.  The inexhaustible beta cell.

Authors:  A I Vinik; W J Kalk; J L Botha; W P Jackson; K C Blake
Journal:  Diabetes       Date:  1976-01       Impact factor: 9.461

7.  Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects.

Authors:  M Perley; D M Kipnis
Journal:  Diabetes       Date:  1966-12       Impact factor: 9.461

8.  Deranged insulin-secretory dynamics in offspring of two diabetic parents after double stimulation with intravenous glucose.

Authors:  L Koncz; J S Soeldner; H Otto; T M Smith; R E Gleason
Journal:  Diabetes       Date:  1977-12       Impact factor: 9.461

9.  C-peptide secretion during the remission phase of juvenile diabetes.

Authors:  E Heinze; W Beischer; L Keller; G Winkler; W M Teller; E F Pfeiffer
Journal:  Diabetes       Date:  1978-06       Impact factor: 9.461

10.  Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects.

Authors:  J P Palmer; J W Benson; R M Walter; J W Ensinck
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.